Amgenvs.Gilead Sciences
AMGN vs GILD · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 1.2× larger than Gilead Sciences by market cap; Gilead Sciences trades at the lower P/E (17.5 vs 25.1); year to date, Amgen leads (+11.0% vs +5.8%).
Side by side
| AMGN | GILD | |
|---|---|---|
| Market cap | $196B | $162B |
| Price | $363.39 | $129.83 |
| Today | −0.1% | −3.7% |
| Return YTD | +11.0% | +5.8% |
| Return 1Y | +21.0% | +13.3% |
| P/E | 25.1 | 17.5 |
| P/S | 5.3 | 5.4 |
| P/B | 21.3 | 6.9 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
AmgenAMGN
Veteran American biotech with a broad portfolio in oncology, immunology and bone diseases — and an obesity candidate (MariTide) in the pipeline.
Full AMGN profile →Gilead SciencesGILD
American biotech company and global leader in HIV treatment, with a growing oncology portfolio.
Full GILD profile →More comparisons in Biotech & innovation
See where AMGN and GILD sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →